Process flow map for both NAS and MAC procedures indicating the steps in the endoscopy process. by Andrew L. Mariotti (17457504)

Subjects:

N-acetilcysteine prevents the <i>A</i>. <i>simplex</i> CE-induced TEER decrease. by Noelia Carballeda-Sangiao (2889611)

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

Base-case results. by Parima Hirunwiwatkul (14797370)

Base-case results. by Unchalee Permsuwan (5478434)

Base case regression results. by Florian Hofer (7377338)

Subjects:

The test steps. by Ruihong Wang (1932328)

Base case results. by Andrea Alcaraz (6573002)

Base-case analysis. by Yiping An (20609789)

“…At a CET of 0.51 times GDP per capita (US$6,394.536), the base-case analysis showed that the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental gain of 0.306 QALYs. …”

JNJ26993135 + BML-111 decreases permeability and enhances ZO-1 and claudin-1 induced by PAF but does not change TEER. by Kameljit K. Kalsi (16496511)

Base-case model inputs. by Rajabali Daroudi (2824832)

Transepithelial electrical resistance (TEER) (N = 6). by Shirko Marcel Shokr (19173337)

“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm²; ALI: 7.73 kΩ*cm²; p<0.05) and day 25 (SMC: 8.19 kΩ*cm²; ALI: 6.44 kΩ*cm²; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

Subjects:

The results of the base case model. by Lei Hua (465535)

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Base-case results. by Mingxi Xie (19812594)

“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

The percentage of significant partial correlations (with sign matching interaction in either direction), as recovered from the base case model. by Susanne Pinto (13767952)